Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001683168-25-002939
Filing Date
2025-04-29
Accepted
2025-04-29 17:00:10
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K xenetic_10ka1-123124.htm   iXBRL 10-K/A 268628
2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER xenetic_ex3103.htm EX-31.3 4300
3 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER xenetic_ex3104.htm EX-31.4 4298
  Complete submission text file 0001683168-25-002939.txt   720539

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE xbio-20241231.xsd EX-101.SCH 3603
5 XBRL DEFINITION FILE xbio-20241231_def.xml EX-101.DEF 6243
6 XBRL LABEL FILE xbio-20241231_lab.xml EX-101.LAB 97695
7 XBRL PRESENTATION FILE xbio-20241231_pre.xml EX-101.PRE 71970
18 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_10ka1-123124_htm.xml XML 5964
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37937 | Film No.: 25888934
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)